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TrkA receptortor after stimulation by NGF is of emerging importance in structural cells in the
context of airway inﬂammatory diseases. We have recently reported the expression of functional TrkA
receptors in human airway smooth muscle cells (HASMC). We have here studied the TrkA trafﬁcking
mechanisms in these cells. TrkA disappearance from the cell membrane was induced within 5 min of NGF
(3pM) stimulation. Co-immunoprecipitation of clathrin-TrkAwas revealed, and TrkA internalisation inhibited
either by clathrin inhibitors or by siRNA inducing downregulation of endogenous clathrin. TrkA internalised
receptors were totally degraded in lysosomes, with no recycling phenomenon. Newly synthesized TrkA
receptors were thereafter re-expressed at the cell membrane within 10 h. TrkA re-synthesis was inhibited by
blockade of clathrin-dependent internalisation, but not of TrkA receptors lysosomal degradation. Finally, we
observed that NGF multiple stimulations progressively increased TrkA expression in HASMC, which was
associated with an increase in NGF/TrkA-dependent proliferation. In conclusion, we show here the occurrence
of clathrin-dependent TrkA internalisation and lysosomal degradation in the airway smooth muscle, followed
byupregulated re-synthesis of functional TrkA receptors and increased proliferative effect in the human airway
smooth muscle. This may have pathophysiological consequences in airway inﬂammatory diseases.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Nerve growth factor (NGF) belongs to the neurotrophin family and is
essential for the development, survival and differentiation of brain and
peripheral neurons [1]. The biological action of NGF ismediated through
activation of its receptors, the high-picomolar-afﬁnity TrkA receptor
(tropomyosin-related kinase A) [2], and the p75NTR receptor binding
neurotrophins and pro-neurotrophins with nanomolar afﬁnity [3].
TrkA is a receptor tyrosine kinase, whose activation by NGF induces
its dimerisation and auto-phosphorylation [4–7]. It has been estab-
lished that upon binding of NGF on neuronal cells, the TrkA receptor is
rapidly endocytosed, and that this is through a clathrin-dependent orhloroquine; CPZ, chlorproma-
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l rights reserved.-independent mechanism [8,9]. The most studied endocytic pathway
for NGF is the retrograde signalling, where NGF activates receptors
expressed at nerve endings, which internalise into endosomes that
retrogradely trafﬁc to the cell body where transduction cascades are
initiated [10–13]. Endocytosis of the TrkA receptor can also induce its
degradation by targeting lysosomes [14–17], or its recycling to the cell
surface by targeting recycling endosomes [18,19].
Retrograde signalling is necessary for neurotrophin receptors in
neuronal cells as a consequence of their complex morphology. Such
endocytic trafﬁcking if occurring in structural cells, would lead to
either degradation or recycling of the TrkA receptor associated with
secondary signalling pathways. However, no studies report TrkA
internalisation and endocytic trafﬁcking in structural cells yet.
We have recently reported the expression of both TrkA and p75NTR
receptors by human airway smooth muscle cells (HASMC) [20], and
clearly demonstrated airway smooth muscle cell proliferation induced
by NGF through activation of the TrkA receptor. We have here studied
the TrkA trafﬁcking in HASMC after stimulation with NGF, and show
TrkA internalisation, degradation and re-expression at the HASMC
membrane, and the consequences on smoothmuscle cell proliferation.
2. Materials and methods
2.1. Reagents and antibodies
Cell culture reagents were purchased from Invitrogen (Cergy Pontoise, France).
Biotinylation assays were performedwith the Cell surface biotinylation and puriﬁcation
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polyclonal antibody, mouse anti-human clathrin heavy chain (CHC) monoclonal
antibody (clone TD.1), mouse anti-HA probe (F-7) monoclonal antibody, control non-
speciﬁc and clathrin small interfering RNAs (siRNAs) were from Santa Cruz
Biotechnologies (Santa Cruz, USA). Goat anti-human TrkA polyclonal antibody used
for immunoprecipitation, as well as human β-NGF were from R&D systems (Lille,
France). HRP-conjugated secondary antibodies were from Jackson Immuno-Research
Laboratories (Soham, Cambridgeshire, United Kingdom). The chemiluminescence kit
was from Amersham Biosciences (Charbonnières, France). Phycoerythrin-conjugated
secondary antibodies were fromMolecular Probes (Eugene, USA), the protease inhibitor
mixture from Roche Applied Science (Meylan, France), the proteasome inhibitors from
Calbiochem (La Jolla, USA). Other inhibitors for lysosomes and clathrin pathways, as
well as the mouse anti-human β-actin monoclonal antibody (clone AC-15) were from
Sigma Aldrich (St Quentin-Fallavier, France). The K252a compound was from Alomone
Labs (Jerusalem, Israel). Tri-Reagent® for RNA extraction was purchased from Molecu-
lar Research Center (Cincinnati, USA). The TrkA and GAPDH primers used for real-time
Q-PCR were from Invitrogen. Online Q-PCR was performed on a Lightcycler® (Roche
Molecular Biochemicals, Mannheim, Germany) using Lightcycler®-Faststart reaction
Mix SYBR Green I (Roche). Cell transfections were performed with a Nucleofector® kit
for human smooth muscle cells (Amaxa, Köln, Germany), using the A-30 program for
optimal density of transfection (60%) and cell survival (70%). Cell proliferation was
assessed by use of the XTT assay (2,3-bis [2-methoxy-4-nitro-5-sulfophenyl]-2H-
tetrazolium-5-carboxanilide) (Cell Proliferation kit II XTT, Roche Diagnostics, Man-
nheim, Germany).
2.2. Cell culture and treatment
Primary cultures were generated as previously described [20,21] with human
airway smooth muscle obtained from healthy lung transplant donors after sudden
death (Center for Biological Resources (CRB), N. Martinet, Nancy, France). Human
airway smooth muscle cells (HASMC) at passage 7 were seeded in 25-cm2 ﬂasks (BD
Falcon™, Le Pont de Claix, France) for mRNA studies, in 75-cm2 ﬂasks for protein studies,
or plated on 4-chamber slides (Nunc, Wiesbaden, Germany) for immunoﬂuorescence
and confocal microscopy.
HASMCwere starved for 48h inaDMEM-F12medium thatwas insulin-free and low in
foetal bovine serum (FBS, 0.3%). Cells were stimulated or not with NGF at 3 pM, a con-
centration previously reported to induce the maximal proliferative effect [20]. Clathrin
recruitment to the cell surface was studied after 2 min of NGF treatment. Clathrin-TrkA
coimmunoprecipitation was studied in cells treated with NGF for 0, 1, 2, 5, 10 and 15 min.
TrkA internalisationwas studied after 0, 5,10 and 15min of NGF treatment in the presence
or absence of the clathrin inhibitors: monodansylcadaverine (50 µM) or chlorpromazine
(100 µM), or in HASMC transfectedwith either control or clathrin siRNA. TrkA degradation
was studied in the presence or absence of proteasome (MG13210 µMor lactacystin 20 µM)
or lysosome (NH4Cl 10 mM or chloroquine 20 µM) inhibitors. Cells were pre-treated with
each inhibitor or its solvent for 1 h before NGF treatment. None of the inhibitors had an
effect by themselves on the parametersmeasured. TrkAmRNA synthesis was studied after
0,1, 2, 3, 5 and 10 h ofNGF treatment. To determine themechanismof TrkA receptormRNA
synthesis, TrkA mRNA expression was measured after 3 h of NGF treatment in cells pre-
treatedwith the tyrosine kinase inhibitor K252a (100 nM),with lysosome inhibitors NH4Cl
(10mM) or chloroquine (20 µM), and onHASMC transfectedwith either control or clathrin
siRNAs. TrkA protein expression and NGF/TrkA-induced HASMC proliferation were ob-
served at 0 (control), 24 (Day 1 D1), 48 (D2), 72 (D3) and 96 h (D4) of NGF treatment, with
NGF stimulation repeated every day.
2.3. Cell transfection and siRNAs
Transient transfection of HASMCwith siRNA (100 nM) was performed on 8×105 cells
suspended in 100 µl of human smooth muscle cells Nucleofector® solution. The Green
Fluorescent Protein (GFP) was used as a control of the transfection efﬁciency by use of
the GFP plasmid provided in the Nucleofector® kit according to the manufacturer's
instructions. Cells were then plated in 75-cm2 ﬂasks (2.4×106 cells per ﬂask) and serum-
starved for 48 h before experiments, with the medium changed 16h after transfection.
Transfection of the control non-speciﬁc commercialised siRNA (siRNAC)designed to target
no human gene product was used as a negative control.
2.4. Western blotting
After starvation and treatment, cells were rinsed in cold PBS and lysed in RIPA
buffer, as previously described [20]. After determination of the total protein content by
the BCA reagent (Sigma Aldrich), 30 to 100 µg of proteinwere subjected to 8% SDS-PAGE
gel, and then blotted onto nitrocellulose. Immunoblotting used a rabbit anti-human
TrkA polyclonal antibody (1:100 in blocking buffer) or a mouse anti-human clathrin
monoclonal antibody (1:200 in blocking buffer), and immunoreactive proteins were
detected by ECL™ reagents. Normalisation was performed in the same conditions with
a mouse monoclonal anti-human β-actin antibody (1:5000 in blocking buffer).
2.5. Cell surface biotinylation assay
Internalisation of the TrkA receptor was analysed by use of a cell surface
biotinylation assay (Cell surface biotinylation and puriﬁcation Kit, Pierce). Brieﬂy,starved cells were treated with NGF (3 pM) for 0, 5, 10 and 15 min. Cells were then
subjected to biotinylation on ice for 2 h with Sulfo-NHS-biotin solution (Sulfosuccini-
midobiotin, 1.5 mg/ml in PBS). Cells were washed 4 times in PBS to remove unbound
reactive biotin. Proteins were extracted using ice-cold RIPA buffer, and the extracts were
clariﬁed by centrifugation at 10000 ×g for 10 min. The resulting supernatant was
divided into 2 parts. One part was kept as the “total TrkA” sample, and the second part
was subjected to immobilized NeutrAvidin™ resin to isolate biotinylated proteins.
Elution of these proteins was then performed with SDS-PAGE buffer containing 50 mM
DTT to separate Sulfo-NHS-Biotin from the extracted proteins. After centrifugation,
Western blotting was performed on both “total TrkA” and this “surface TrkA” samples.
Normalisation for “surface TrkA” samples was done by staining total surface proteins
with Ponceau-red.
2.6. Clathrin and TrkA receptor coimmunoprecipitation
After starvation and treatment, cells were rinsed in cold PBS and lysed in RIPA
buffer. TrkA immunoprecipitation was performed as previously described [20]. Brieﬂy,
after centrifugation and determination of the total protein content, 500 µg of pro-
tein was incubated for 2 h at +4 °C with a goat anti-human TrkA polyclonal anti-
body (4 µg), and then incubated overnight at +4 °C with 20 µl A/G protein-agarose
beads for antibody complexing. After 3 centrifugations, the pellet was washed and
resuspended in 60 µl 2× Laemmli buffer, heated at 100 °C and centrifuged. Western
blotting was performed using a mouse monoclonal antibody against human clathrin
heavy chain (CHC) (1:100 in blocking buffer). Controls were also performed by
immunoprecipitating CHC (3 µg monoclonal antibody), followed byWestern blotting to
reveal the TrkA receptor (rabbit polyclonal anti-human TrkA antibody,1:100 in blocking
buffer).
2.7. Immunoﬂuorescence staining and confocal microscopy
HASMC were grown on 4-well chamber slides and starved at 70% conﬂuence for
24 h. Control and NGF-treated cells were rinsed in PBS, ﬁxed and permeabilized in
acetone/methanol 50/50 v/v for 3 min on ice, and rinsed in PBS. After blockade of non
speciﬁc binding by incubation of 10% foetal calf serum and 1% bovine serum albumin in
PBS for 30min and rinsing, amousemonoclonal antibody against human clathrin heavy
chain (CHC) (1 µg/ml) was incubated overnight at +4 °C, followed by an anti-mouse IgG
(2 µg/ml) conjugated with phycoerythrin for 1 h at room temperature. The slides were
cover slipped using a ﬂuorescent mounting medium (Dako, Trappes, France) for
confocal microscopy. TheMRC-1024ES confocal equipment mounted on a Nikon Eclipse
TE 300 inverted microscope (Bio-Rad, Hertfordshire, UK) was used for the optical
sectioning of cells. Excitation line at 488 nm of a krypton/argon laser was used to
illuminate a Nikon 60× immersion objective. Emitted light was detected with two
photomultipliers through a selected band pass ﬁlter of 578 nm. Digital images were
recorded using LaserSharp Software (Bio-Rad). Confocal Assistant was used for image
analysis (version 4.0.2 by TC Brelje, University of Minnesota, USA).
2.8. Extraction of total RNA and reverse transcription
After starvation, control or NGF-treated cells were added with 1 ml Tri-Reagent®
and total RNAwas extracted as previously described [20,21]. A secondary extractionwas
performed to avoid any genomic DNA contamination. One µg total RNA was then
reverse transcribed with 1 U/µl Rnase H minus-Moloney leukaemia virus reverse
transcriptase in the RT buffer.
2.9. Quantitative determination of TrkA mRNA by real-time quantitative PCR
One µl of the RT product was ampliﬁed in a 1× PCR reaction buffer containing 2 mM
MgCl2 and 2 µl reaction mix with FastStart Taq DNA polymerase, dNTP mix, SYBR Green I
(Lightcycler®-Faststart reaction Mix SYBR Green I), with 0.4 µM of each primer: sense
(20 pb): 5′CCCCATCCCTGACACTAACA and antisense (20 pb): 5′GCACAAGGAGCAGCGTA-
GAA in a 20 µl ﬁnal volume for 40 cycles (denaturation: 15 s at 95 °C, hybridisation: 10 s
at 56 °C, elongation: 6 s at 72 °C) in the Lightcycler®. A standard curve was constructed
after speciﬁc TrkA cDNA ampliﬁcation, extraction on agarose (Qiaex II®, Qiagen S.A.,
Courtaboeuf, France), and quantiﬁcation by Picogreen® ﬂuorescence (DNA Quantiﬁcation
reagent, Interchim, Montluçon, France). The speciﬁcity of the 131 bp PCR product was
validated by the fusion curve obtained after ampliﬁcation (Lightcycler®), by electropho-
resis and molecular sequencing. Results were normalised to expression of glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), quantiﬁed by Lightcycler® using 0.4 µM of
each primer: sense (22bp): 5′-GGTGAAGGTCGGAGTCAACGGA-3′ and antisense (22bp):
5′-GAGGGATCTCGCTCCTGGAAGA-3′ in a 20µlﬁnal volume for 40 cycles (denaturation: 15 s
at 95 °C, hybridisation: 10 s at 57 °C, elongation: 10 s at 72 °C).
2.10. Cell proliferation assay
Cell proliferation was measured by the XTT assay according to the manufacturer's
instructions, as previously described [20]. Brieﬂy, cells were seeded in 96-well culture
plates (3000 cells per well) in low-FBS (0.3%), insulin-free, DMEM-F12medium, allowed
to adhere for 3 h, and then treated with NGF or its solvent (PBS-1% bovine serum
albumin) alone for 0 to 4 days. Cells were then exposed to XTT (1 mg/ml, 3 h) and
absorbance was measured at 450 nm.
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Western blotting intensities are expressed as arbitrary units (AU). TrkA receptormRNA
levels are expressed as the ratio of TrkAcDNA (fg)/GAPDHcDNA (ng). TrkA receptor protein
levels are expressed as TrkAWestern blotting intensities in arbitrary units, and presented
on graphs either as a percentage of internalisation compared to surface TrkA basal
expression, or as a percentage of total TrkAbasal expression. Proliferationwas calculated as
a percentage of the solvent-treated time-matched controls. Results are presented on
graphs asmeans±S.E.M. Parametric datawere analysed by a one-way ANOVA followed by
a Student–Newman–Keuls multiple comparison test, or a Dunnett test when comparing
several variables to the same control. Non parametric data were analysed by a Kruskal–Fig. 1. Involvement of clathrin-dependent mechanisms in TrkA internalisation induced by NG
NGF (3 pM) for 2 min and clathrin redistribution in HASMC was visualised by immunoﬂuo
clathrin heavy chain (CHC) revealed by an anti-mouse IgG conjugated with phycoeryth
immunostainings presented are representative of 3 independent experiments (N for cell nu
treatment. Cells were treated with NGF (3 pM) for 0, 1, 2, 5, 10 and 15 min and recruitment
antibody was used to immunoprecipitate (IP) cell lysates, and the blots were probed (IB) for cl
quantiﬁcation of the amount of clathrin observed in TrkA immunoprecipitates and is expresse
C) Clathrin-dependent internalisation of the TrkA receptor. Internalisation of the TrkA recept
TrkA expression at the cell membrane (“Surface TrkA”) after NGF treatment, with TrkA total e
receptor induced by NGF (3 pM, 15 min) was studied in HASMC transfected or not with co
clathrin inhibitors monodansylcadaverine (MDC, 50 μM) or chlorpromazine (CPZ, 100 μM).
untreated control cells and are presented as means (blocks)±S.E.M. (bars) of three independe
and ⁎⁎: pb0.01 versus NGF 3 pM. On the right, a representative Western blot shows the decr
(siRNA Clath), whereas the non-speciﬁc control siRNA (siRNA C) did not modify it. β-Actin,Wallis test, followed by a Dunn's multiple comparison test. All data were analysed at a
pb0.05 level of signiﬁcance.
3. Results
3.1. Clathrin-dependent internalisation of the TrkA receptor in HASMC
We ﬁrst show that clathrin was recruited to the cell membrane
in response to NGF (3 pM) in HASMC (Fig. 1A). There was a clearF in HASMC. A) NGF causes clathrin redistribution in HASMC. Cells were stimulated with
rescence and confocal microscopy, using a mouse monoclonal antibody against human
rin as described in Materials and methods. The width of each panel is 40 μm and
cleus). B) Coimmunoprecipitation of clathrin and TrkA receptors in HASMC after NGF
of clathrin to the TrkA receptor was visualised by coimmunoprecipitation. An anti-TrkA
athrin (top), or for TrkA (bottom) to control for protein loading. The graph represents the
d as arbitrary units (AU). This result is representative of three independent experiments.
or was appreciated by use of a cell-surface biotinylation assay, to observe the decrease in
xpression inwhole cell lysates used as controls (“Total TrkA”). Internalisation of the TrkA
ntrol (siRNA C) or clathrin (siRNA Clath) siRNAs, or after 1h of pre-treatment with the
Data are expressed as a percentage of TrkA expression at the cell surface compared to
nt experiments performed in duplicate. ###: pb0.001 versus control; NS: non signiﬁcant
ease in endogenous clathrin protein levels after transfectionwith siRNA against clathrin
probed in the same blots was used to control for protein loading.
Fig. 2. Degradation pathways of the TrkA receptor after activation by NGF and
internalisation in HASMC. Cells were treated with NGF (3 pM) for 1, 2 or 5 h, alone or
after 1 h of pre-treatment with the lysosomes inhibitors chloroquine (Chloro 20 μM) and
ammonium chloride (NH4Cl 10 mM), or with the proteasome inhibitors MG132 (10 μM)
and lactacystin (Lacta 20 μM). Degradation of the TrkA receptor was visualised by the
decrease in total TrkA expression after NGF treatment. β-Actin, probed in the same
blots, was used to control for protein loading.Western blots shown are representative of
3 independent experiments performed in duplicate.
Fig. 3. TrkA re-synthesis after NGF treatment in HASMC. A) Kinetics of TrkA mRNA
synthesis. Cells were treated with NGF (3 pM) for 0, 1, 2, 3, 5 and 10 h and expression of
TrkA mRNA was measured by real-time Q-PCR (Lightcycler®). Data are expressed as
TrkA cDNA (fg)/GAPDH cDNA (ng) and are presented as means (blocks)±S.E.M. (bars) of
3 independent experiments performed in duplicate. NS: non-signiﬁcant, ⁎⁎: pb0.01
and ⁎⁎⁎: pb0.001 versus control. B) Kinetics of TrkA protein re-synthesis. Cells were
treatedwith NGF (3 pM) for 0, 5,10 and 24 h and TrkA total or surface protein expression
was visualised byWestern blotting after cell surface biotinylation, as described in Fig. 1.
Western blots shown are representative of 3 independent experiments performed in
duplicate. C)Mechanisms involved in generating the signal of TrkA re-synthesis. HASMC
were treated for 3 h with NGF (3 pM) alone, or after 1 h pre-treatment with the kinase
inhibitor K252a (100 nM), the lysosomes inhibitors chloroquine (Chloro 20 μM) and
ammonium chloride (NH4Cl 10 mM). TrkA mRNA synthesis was also measured after
NGF treatment (3 pM) in cells transfected with the control non-speciﬁc siRNA (siRNA C
100 nM) or with the clathrin siRNA (siRNA Clat 100 nM). Expression of TrkA mRNAwas
measured by online Q-PCR (Lightcycler®). Data are expressed as TrkA cDNA (fg)/GAPDH
cDNA (ng) and are presented as means (blocks)±S.E.M. (bars) of three independent
experiments performed in duplicate. ###: pb0.001 versus control. NS: non-signiﬁcant,
⁎⁎: pb0.01 and ⁎⁎⁎: pb0.001 versus NGF 3 pM.
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with a strong staining at speciﬁc locations near the cell membrane. By
contrast in untreated HASMC, clathrin immunoreactivity was diffuse
throughout the cytoplasm (Fig.1A).We also showclathrin and TrkA co-
immunoprecipitation in HASMC after 1 to 10 min of NGF treatment,
maximal at 2–10 min and decreasing after 15 min (Fig. 1B). Similar
results were observed in co-immunoprecipitation experiments of
clathrin and TrkA revealed by immunoblotting.
The TrkA receptor was constitutively expressed at the cell
membrane of HASMC, as revealed by TrkA immunoblotting in the
biotinylated surface protein samples. After NGF treatment (3 pM),
expression of the surface TrkA receptor rapidly decreased (89±2% at
15 min) (Fig. 1C), suggesting NGF-induced TrkA receptor internalisa-
tion. Total TrkA expression was not modiﬁed during this time of NGF
treatment.
HASMC transfection with clathrin siRNA induced a signiﬁcant
decrease in clathrin protein expression (51±5% inhibition, pb0.01),
whereas control non-speciﬁc siRNA did not modify it (Fig. 1C, right
panel). In addition, control expression of both total and surface TrkA in
HASMC was not modiﬁed after transfection with either clathrin or
control siRNAs (not shown). By contrast, after 15 min of NGF
treatment, the decrease in surface TrkA protein expression was
inhibited by 47±7% in cells treated with siRNA for clathrin (pb0.01),
whereas it remained unmodiﬁed in cells transfected with the control
siRNA (Fig. 1C).
Involvement of clathrin in NGF-induced internalisation of the TrkA
receptor was further demonstrated by use of inhibitors of the clathrin
pathway, monodansylcadaverine and chlorpromazine, with inhibition
of the decrease in surface TrkA expression by 58±1 and 51±3%,
respectively (Fig. 1C; pb0.01 for both).
3.2. Degradation of the TrkA receptors in lysosomes
The total TrkA receptors totally disappeared within 5h of NGF
treatment (Fig. 2), indicating degradation of the receptor rather than a
recycling process. This degradationwas totally blocked by inhibitors oflysosomes, chloroquine or NH4Cl, which did not by themselvesmodify
the total TrkA expression. By contrast, the proteasome inhibitors
MG132 and lactacystin had no effect (Fig. 2), clearly indicating
lysosomal degradation of the TrkA receptors after NGF stimulation of
HASMC.
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After NGF treatment (3 pM), a signiﬁcant and time-dependent
enhancement in TrkA mRNA expression was observed in HASMC
(Fig. 3A). A 2-fold maximal increase occurred after 3 h of NGF
treatment (from 35±3 to 71±6 fg TrkA cDNA/ng GAPDH cDNA,
pb0.001), with levels progressively returning to baseline levels within
10h. TrkAmRNA synthesis was followed by TrkA protein synthesis and
re-expression at the cell surface within 10–24h of NGF treatment
(Fig. 3B).
We further investigated whether TrkA activation, internalisation
and/or degradation participated into the signalling process generating
TrkA mRNA synthesis. We ﬁrst show that the increase in TrkA mRNA
levels, measured after 3 h of NGF treatment, was abolished when pre-
treating HASMC with the kinase inhibitor K252a (pb0.001) (Fig. 3C),
indicating that TrkA activation is necessary to the induction process. In
addition, the increase was also blocked when the expression of
clathrinwas downregulated after siRNA transfection (60±6% decrease,
pb0.01), without being modiﬁed after control siRNA transfection in
HASMC. This indicates that the internalisation process is directlyFig. 4. Expression and functionality of neo-synthesised TrkA receptors after NGF
repeated treatment in HASMC. A) Expression of total TrkA protein after repeated NGF
stimulations. HASMCwere treatedwithNGF (3 pM)during 24 (Day1), 48 (D2), 72 (D3) or
96h (D4) and the increase in total TrkA protein was visualised each day by Western
blotting. Data are expressed as a percentage of increase in TrkA expression compared
to corresponding non treated time-matched controls and are presented as means
(blocks)±S.E.M. (bars) of three experiments performed in duplicate. NS: nonsigni-
ﬁcant, ⁎: pb0.05 and ⁎⁎: pb0.01 versus control. B) Proliferation of HASMC after repeated
NGF stimulations. Cells were treated as described above and cell proliferation was
measured each day after NGF stimulation (3 pM) by the XTT technique, as described in
Materials andmethods. Data are expressed as a percentage of proliferation compared to
untreated control cells and are presented as means (blocks)±S.E.M. (bars) of three
experiments performed in triplicate. NS: non signiﬁcant, ⁎⁎: pb0.01 and ⁎⁎⁎: pb0.001
versus control.linked to this induction of TrkA resynthesis. By contrast, the inhibition
of TrkA lysosomal degradation by the lysosome inhibitors, NH4Cl and
chloroquine, had no effect on TrkA mRNA synthesis (Fig. 3C).
3.4. Increased expression and functionality of the TrkA receptor after
repeated NGF stimulations of HASMC
After 24 h of NGF treatment (Day1), a trend towards an increase in
TrkA protein expressionwas observed, but this was not signiﬁcant (30±
15% increase, NS) (Fig. 3B and 4A). Cells were treated again every 24 h
with NGF for 4 days, and TrkA protein expression was measured 24 h
after each NGF stimulation. We observed a time-dependent increase
in TrkA protein expression compared to the non treated time-matched
controls, signiﬁcant after 2 stimulations (D2, 69±21% increase, pb0.05),
and reaching a plateau after 3 stimulations (D3: 121±11% increase,
pb0.01; D4: 111±32% increase, pb0.01) (Fig. 4A). In parallel, the func-
tionality of the newly synthesised TrkA receptors was demonstrated by
their physiological effect, i.e. HASMC proliferation: each NGF stimula-
tion induced a progressive increase in HASMC proliferation (D1: 4±1%
increase, NS; D2: 7±1% increase, pb0.01; D3: 9±1% increase, pb0.001;
D4: 13±2% increase, pb0.001), in parallel to the progressive increase in
TrkA protein expression (Fig. 4B).
4. Discussion
We here report that activation of the TrkA receptor by NGF at
picomolar concentrations is followed by TrkA internalisation in human
airway smooth muscle cells, and that this is mediated through a
clathrin-dependent mechanism. We further show that TrkA receptors
are then degraded in lysosomes, and that this degradation is total
within 5h. Degradation is followed by TrkA mRNA and protein
synthesis induced bya signal generated during the clathrin-dependent
TrkA internalisation. Finally, newly synthesised TrkA receptors are
functional and repeated NGF stimulations of HASMC induce a
progressive increase in TrkA protein expression, in parallel with an
increase in NGF/TrkA-induced HASMC proliferation (Fig. 5).
First, we show here the trafﬁcking of the TrkA receptor in structural
HASM cells, and this is a new ﬁnding. NGF was ﬁrst known for its
essential effect on neuronal cells, and trafﬁcking of the TrkA receptor
has beenwidely studied there, in particular since retrograde signalling
occurs in neuronal cells (for reviews: [22,23]). We show here that
regulation of the TrkA receptor expression after NGF stimulation also
occurs in structural cells through receptor internalisation and
degradation. This is in accordance with the reported trafﬁcking of
receptors with tyrosine kinase activity of other types in other
structural cells, for example the receptor for epidermal growth factor
in human kidney epithelial cells [24] or mouse NR6 ﬁbroblasts [25], or
the receptor for insulin in adipocytes [26]. Moreover, internalisation of
the TrkA receptor in HASMC occurs very rapidly after NGF activation.
Indeed, treatment by NGF induces clearing of almost 90% of the
receptor from the cell surface within 15 min of NGF treatment. This is
consistent with reports of TrkA internalisation in neuronal cells, in
particular in PC12 cells where 70% of the surface receptors were
internalised after 15–20 min of NGF treatment [14]. By contrast,
whereas Jullien and co-workers reported a maintained low level of
TrkA expression at the cell surface of PC12 cells even after prolonged
NGF exposure [14], our study clearly indicates that the TrkA receptor is
totally removed from the HASM cell surface within 30 min of NGF
treatment. It is to be noted however that the concentrations of NGF
used were very different in both studies, within the picomolar range
activating the TrkA receptor in our study and in the nanomolar range
for Jullien and co-workers. This suggests that trafﬁcking of the TrkA
receptor differs in function of the dose of NGF and/or of the cell type
(HASMC vs PC12, respectively).
Furthermore, we show that TrkA internalisation was totally
blocked by clathrin inhibitors as well as when clathrin expression
Fig. 5. Schematic representation of TrkA trafﬁcking after NGF activation in human airway smooth muscle. NGF at picomolar concentrations induces 1) activation of the TrkA receptor
in human airway smooth muscle cells, followed by 2) TrkA internalisation through a clathrin-dependent mechanism and 3) TrkA total degradation in lysosomes. TrkA receptors are
then 4) neo-synthesised upon a signal generated during TrkA internalisation, and re-expressed at the cell membrane. These newly synthesised TrkA receptors are functional and
repeated NGF stimulations of HASMC induce 5) an increase in TrkA protein expression, in parallel with 6) an increase in NGF/TrkA-dependent effects such as cell proliferation.
: indirect mechanism; : activation.
1969V. Freund-Michel, N. Frossard / Biochimica et Biophysica Acta 1783 (2008) 1964–1971was downregulated by siRNA, clearly indicating involvement of
clathrin in this mechanism. This is in full agreement with studies
in PC12 cells showing clathrin redistribution after NGF-induced
TrkA activation [10], and rapid endocytosis of the TrkA receptor in
a clathrin-dependent manner in hippocampal [27] or dorsal root
ganglia [28] neurons in primary culture.
Analysis of the total cellular amount of the TrkA receptor at longer
times of NGF treatment showed that internalised receptors are further
degraded. Inhibitors of lysosomal enzymes totally blocked this TrkA
degradation, indicating that TrkA degradation occurs in lysosomes.
This is in accordance with results in PC12 cells, where lysosome
inhibitors blocked TrkA degradation [14], as well as with degradation
of other tyrosine kinase receptors like the EGF receptor in lysosomes
in mouse 3T3 or NR6 ﬁbroblasts [29,30]. Indeed, the TrkA receptor
protein totally disappeared in HASMC within 5 h of NGF treatment,
suggesting that all TrkA receptors expressed in HASMC are activated
by NGF and further degraded. This result also suggests that
intracellular pre-formed TrkA pools do not exist in HASMC, since
Western blot experiments of the TrkA expression show a unique band
at 140 kDa mapping the mature TrkA receptor in our study, whereas
another TrkA form of 110 kDa has been evidenced with the same
antibody in PC12 cells [14]. Finally, as TrkA expression totally
disappears after 5h of NGF treatment, thus indicating TrkA total
degradation, it seems improbable that any TrkA receptors trafﬁc to the
recycling pathway as shown in Chinese hamster ovary ﬁbroblasts [19],
or in PC12 cells [18].Neo-synthesis of the TrkA receptor was thereafter evidenced in our
study, with maximal increase in TrkA mRNA levels at 3 h of NGF
treatment. We additionally show that this TrkA mRNA synthesis was
blocked when TrkA internalisation was blocked. This is an original
result, which suggests generation of the signal responsible for TrkA re-
synthesis during clathrin-dependent TrkA internalisation. This is
consistent with the fact that blocking the TrkA degradation by
lysosomes, which occurs after TrkA internalisation, does not affect
TrkA mRNA synthesis. Clathrin-dependent internalisation of the TrkA
receptor in neuronal cells [28] leads to formation of signalling endo-
somes that serve as a signalling platform and help contacts between
TrkA receptors and intracellular signalling proteins [10,11,31–33].
Some of these effectorsmight therefore participate into the generation
of the signal inducing TrkA re-synthesis in HASMC.
TrkA mRNA was followed by TrkA protein synthesis with
detection of TrkA protein re-expression at the cell surface within
10 h of NGF treatment. The increase in TrkA expression observed after
NGF treatment is very surprising, since endocytic trafﬁcking target-
ing receptors to lysosomes induce rather a down-regulation of the
total number of receptors at the cell surface. This has been evidenced
for other tyrosine-kinase receptors such as for the EGF receptor
in vitro in a murine ﬁbroblast B82 cell line [34] or in vivo in several
organs in the rat [35], for the TrkB receptor in primary cultures of
cerebellar granule neurons [17], and also for the TrkA receptor itself
in vitro in rat cortical neurons [15]. We add to this fully original
ﬁnding that repeated stimulations of HASMC with NGF induced a
1970 V. Freund-Michel, N. Frossard / Biochimica et Biophysica Acta 1783 (2008) 1964–1971progressive increase in TrkA protein expression, and demonstrate
that these receptors are functional since an increase in NGF-induced
TrkA-dependent HASMC proliferation is measured. Since TrkA
receptors are expressed by the human airway smooth muscle
in vivo [45], such a mechanism, if occurring in vivo, might be of
importance in inﬂammatory airway diseases such as asthma.
However, although an increased expression of NGF occurs in various
allergic conditions [36–43], modulation of TrkA expression differs in
function of experimental models and/or disease [37,41,44]. More
importantly, the expression and turnover of TrkA on the airway
smooth muscle during allergic airway diseases in particular asthma
in vivo are not yet reported. This will be an important point to
answer to in the future, since an increase in TrkA expression, if
occurring in vivo, might potentiate NGF effects in the asthmatic
airways, therefore participating for instance to the reported hyper-
plasia of the airway smooth muscle. Understanding the relevance of
this mechanism would therefore strengthen our knowledge on the
role of the neurotrophins in allergic diseases and asthma.
In conclusion, we here report that activation of the TrkA receptor
by NGF at picomolar concentrations causes its internalisation
mediated by clathrin-dependent pathways, followed by lysosomal
degradation. This adds to the knowledge on trafﬁcking of the TrkA
receptor that had never been evidenced before in structural cells. Our
results also show that repeated TrkA activation in the airway smooth
muscle leads to increased TrkA expression and effects that may have
increased pathophysiological consequences. These results, together
with ﬁndings in animal models of atopic dermatitis [45] or of asthma
[44,46], therefore suggest the TrkA receptor as an interesting target in
the development of new therapeutic approaches in the treatment of
allergic diseases.
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